126 related articles for article (PubMed ID: 5484511)
1. [Influence of noracycline administered for dysmenorrhea on certain biologic functions of the female organism. Its effect on electrolyte metabolism].
Jabloński K; Giermańska T; Filc-Bauer A
Pol Tyg Lek; 1970 Nov; 25(47):1789-92. PubMed ID: 5484511
[No Abstract] [Full Text] [Related]
2. [The effect of noracycline administered in menstruation disorders on certain biological functions of the female organism. Effects on the protein metabolism].
Jabloński K; Giermańska T; Filc-Bauer A
Pol Tyg Lek; 1970 May; 25(18):635-7. PubMed ID: 5429830
[No Abstract] [Full Text] [Related]
3. [Effect of noracycline administered in menstruation disorders on various biological functions of the female organism. The secretion of ovarian hormones].
Jabloński K; Zymek-Giermańska T; Filc-Bauer A
Pol Tyg Lek; 1971 Apr; 26(14):505-7. PubMed ID: 5581640
[No Abstract] [Full Text] [Related]
4. [Effect of noracycline administered in menstrual disturbances on certain biological functions in the female organism].
Jabloński K; Giermańska T; Filc-Bauer A
Pol Tyg Lek; 1970 Sep; 25(36):1361-3. PubMed ID: 5470622
[No Abstract] [Full Text] [Related]
5. A new progestogen-estrogen combination for gynecologic therapy and contraception.
Linthorst G
Int J Fertil; 1966; 11(1):35-45. PubMed ID: 5936282
[No Abstract] [Full Text] [Related]
6. [Clinical experiences with gestagen therapy of various gynecologic diseases].
György G; László J
Orv Hetil; 1967 Jun; 108(25):1169-71. PubMed ID: 6077686
[No Abstract] [Full Text] [Related]
7. [Handling of a synthetic progestative in a psychiatric milieu].
Dubor P; Favre-Tissot M; Guyotat J; Haour P; Simonnet ; Vantheemsche G
J Med Lyon; 1966 Oct; 47(106):1379-85. PubMed ID: 5928220
[No Abstract] [Full Text] [Related]
8. [Treatment with ovariostatic drugs in premenopausal syndromes. Cytological control].
Subrizi DA; Pieroni G
Riv Ostet Ginecol; 1966 Jun; 21(6):320-6. PubMed ID: 5963561
[No Abstract] [Full Text] [Related]
9. [Treatment of dysfunctional uterine hemorrhages and amenorrheas using a progestagen-estrogen combination].
Brehm H; Karsznia R; Prinz W; Schmidt G
Med Monatsschr; 1972 Dec; 26(12):577-9. PubMed ID: 4663633
[No Abstract] [Full Text] [Related]
10. [Estroprogestinic associations in the preclimacteric syndrome: blood coagulation problems].
Schubert L; Giarola P; Gibelli A; Iurlaro F
G Gerontol; 1969 Nov; 17(11):1059-66. PubMed ID: 5397790
[No Abstract] [Full Text] [Related]
11. [Clinical investigations on the usefulness of Lyndiol for contraceptive and therapeutic purposes].
Liebhart S; Trebicka-Kwiatkowska B
Endokrynol Pol; 1966; 17(6):717-28. PubMed ID: 5341992
[No Abstract] [Full Text] [Related]
12. [Clinical study of a synthetic progestagen at low doses].
Gaudefroy M
Gynecol Prat; 1966; 17():337-43. PubMed ID: 5987259
[No Abstract] [Full Text] [Related]
13. [Clinical experimentation with Ovanon].
Durandeau A
Rev Bras Med; 1968 Apr; 25(4):241-5. PubMed ID: 5747876
[No Abstract] [Full Text] [Related]
14. [Hormonal treatment of juvenile menstruation disorders].
Sas M
Fortschr Med; 1974 May; 92(15):641-2. PubMed ID: 4829461
[No Abstract] [Full Text] [Related]
15. [Tolerance of the gestagen-estrogen combination Noracyclin in contraception and gynecologic indications].
Willmes HG
Med Klin; 1967 Jun; 62(24):951-4. PubMed ID: 5627276
[No Abstract] [Full Text] [Related]
16. Effect of some steroid contraceptives on serum inorganic constituents of lactating goats.
Abdel Kader MM; Abdel-Hay A; el-Safouri S
J Egypt Med Assoc; 1970; 53(2):170-8. PubMed ID: 5529010
[No Abstract] [Full Text] [Related]
17. [The therapeutic use of the sequentially administered oral ovulation inhibitor Ovanon].
Gimes R; Tóth F
Dtsch Med J; 1969 Dec; 20(23):718-9. PubMed ID: 5397037
[No Abstract] [Full Text] [Related]
18. [The influence of sistometril on the LH excretion in the urine of women with menstruation disorders].
Wawryk R; Samochowiec E; Krupa B; Lipski J
Ginekol Pol; 1969 Aug; 40(8):903-10. PubMed ID: 5820768
[No Abstract] [Full Text] [Related]
19. [Ovulen, its effect on the endometrium, uterine cervix and ovary].
Muller G; Dehalleux JM; Ritter J; Philippe E; Gandar R
Gynecol Obstet (Paris); 1968; 67(5):521-32. PubMed ID: 5730661
[No Abstract] [Full Text] [Related]
20. [Action duration of lynestrenol as a component of an anticontraceptive agent].
Schmidt-Elmendorff H
Int Z Klin Pharmakol Ther Toxikol; 1971 Dec; 5(3):352-5. PubMed ID: 5148892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
